| |
Generative AI has the potential to accelerate innovations across the value chain, from R&D to commercialization. Watch this webinar series to learn why nine out of the top 10 biopharma organizations use AWS for machine learning and analytics. Watch now. .png)
|
|
Today’s Big NewsAug 30, 2023 |
|
Government Biotechnology Innovation Summit Convenes September 27-28 in National Harbor, MD. Hear from government leaders at the forefront on how biotechnology is transforming the economic, agricultural, healthcare and security landscape of the U.S. Learn more. .png)
|
|
| By Nick Paul Taylor Novo Nordisk is continuing to seek out obesity assets, paying 15 million euros ($16 million) to snap up Embark Biotech in its second weight loss takeover in quick succession. |
|
|
|
| Philadelphia, PA |  |
|
|
By Zoey Becker After 16 years on the market, Takeda's blockbuster ADHD med Vyvanse has finally reached its patent cliff. And the FDA's approval of several generics comes amid a U.S. shortage of the drug. |
By Conor Hale Separately at the annual meeting of the European Society of Cardiology in Amsterdam, Siemens Healthineers and Philips trained their spotlights on how artificial intelligence will change the way clinicians examine patients for heart disease. |
By Max Bayer Scientists at the University of Oxford are once again teaming up CEPI to develop new prototype vaccines aimed at preventing future pandemics. The Norwegian preparers have committed $80 million toward the initiative, which will build on Oxford's adenovirus vaccine platform. |
|
Wednesday, September 6, 2023 | 2:00 PM ET / 11:00 AM PT Attendees will learn about the latest tools for interacting with medical images, how to guide readers through labeling workflows, and streamlining adjudication and data standardization. Discussions will include real-world use cases of how pharma companies are enhancing AI development by optimizing reader workflows. Register now. 
|
|
By Angus Liu Even without an FDA approval, Roche’s cancer drug Avastin is widely used by doctors to treat certain eye diseases. Outlook Therapeutics has been trying to get an official approval for a reformulated version, but instead got a rejection letter. |
By Gabrielle Masson Notch Therapeutics is shuttering one of its three cell therapy centers—which also serves as its headquarters—and is working to find positions for its displaced staff at other companies in the industry. |
By Andrea Park Lucid Hearing unveiled the “highest premium option” in its OTC line of hearing aids this week: The earbud-like $1,300 Tala. |
By Nick Paul Taylor FibroGen’s rotten run continues. The biotech reported its fourth phase 3 failure in as many months after the market closed Tuesday, flunking a second Duchenne muscular dystrophy trial in quick succession to send it deeper into the mire. |
By Fraiser Kansteiner After a tumultuous year of manufacturing hiccups, executive turnover and dwindling revenues, Catalent is linking up with Elliott Management. The CDMO giant struck a cooperation agreement with the activist investor group as it announced fourth-quarter revenues and unveiled a sweeping governance shakeup. |
By Conor Hale Abbott aims to build optical coherence tomography into a preferred tool for guiding the placement of stents that increase blood flow to the heart muscle. But a pair of major late-breaking studies comparing OCT to other imaging techniques have delivered mixed results. |
By Angus Liu,Kevin Dunleavy,Eric Sagonowsky In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
Whitepaper In oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Research Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
| |
|
